[Mesothelium and malignant mesothelioma of the pericardium]. / O mezotelii i zlokachestvennoi mezoteliume perikarda.

Malignant mesothelioma of the pericardium is characterized by atypical solid growth of mesothelium with formation of atypical cavities, slits surrounded by a fibrous stroma. Unless early biopsy, diagnosis and surgery, the prognosis is unfavourable. It is desirable to create immunomorphological test for mesothelium. Recognition of epithelioid, fibrous and mixed forms of mesotheliomas is disputable.

[Use of navoban for nausea and vomiting caused by chemotherapy for malignant tumors]. / Ispol'zovanie navobana dlia kypirovaniia toshnoty i rvoty pri khimioterapii zlokachestvennykh novoobrazovanii.

The antiemetogenic effect of navoban (Sandoz) was studied in 26 patients receiving chemotherapy, with application of platidiam in 22 cases included. No vomiting was registered. Nausea was observed in 9 cases within the first 24 hrs and a slight reduction in appetite--in 13 cases. Navoban proved one of the most potent antiemetics devoid of any untoward side-effects.

[The use of tumor markers in the diagnosis and treatment monitoring of malignant tumors of the female genitalia]. / Ispol'zovanie opukholevykh markerov v diagnostike i monitoringe lecheniia zlokachestvennykh opukholei zhenskikh polovykh organov.

Levels of carcinoembryonic antigen (CEA), CA-19-9, CA-125, and mucin-like associated tumor antigen (MAA) were measured in the blood sera of 108 patients with uterine cervix and body, and ovarian carcinomas before treatment, and in those with ovarian carcinoma over the course of treatment to monitor its efficacy. The findings indicate that neither CEA nor MAA were diagnostically informative in malignant tumors of female genitals, and in uterine cervix cancer none of the tumor markers was diagnostically valuable. In neglected cases of uterine body cancer blood levels of CA-19-9 and CA-125 were elevated. In ovarian carcinoma CA-125 levels varied statistically significantly (p < 0.05) in various stages of the disease. CA-125 measurements are recommended for monitoring the treatment efficacy in patients with ovarian cancer.

[Tumor markers in the diagnosis and prognosis of breast cancer]. / Znachenie opukholevykh markerov v diagnostike i prognozirovanii techeniia raka molochnoi zhelezy.

Serum levels of markers--mucinoid associated antigen (MAA), carcinoembryonal antigen (CEA) and carbohydrate antigen (CA-19-9) were measured in 78 breast cancer patients using enzyme immunoassay. It was found that MAA was most reliable of the above markers in staging breast cancer. A combined study of the latter is advisable in determination of breast cancer dissemination, in the control over the disease course and prognosis.

[Diagnostic and treatment problems in malignant neoplasms]. / Nekotorye voprosy diagnostiki i lecheniia zlokachestvennykh novoobrazovanii.

The article gives the comparative estimation between the state of oncological aid in the system of the civilian health care and military medicine. The authors analyse the most frequent defects in diagnosis and treatment of malignant new-growths. The article focuses the attention of physicians on an early diagnosis of malignant new-growths, necessity to improve their oncology-oriented skill, and render an adequate oncological aid to the servicemen.

[Therapeutic procedure in synchronous and metachronous breast cancers]. / O lechebnoi taktike pri sinkhronnykh i metakhronnykh rakakh molochnoi zhelezy.

The article is written in response to the discussion, raised by L. Yu. Dymarsky and R. T. Popova on pages of the Journal "Voprosy Onkologii" No 8, 1978. The writers have observed 45 patients with bilateral involvement of mammary glands. In stages I and II the primary bilateral involvement of mammary glands was noted in 27 of 29 patients (93.1%), in stages III and IV metastatic cancer of the opposite gland prevailed in 62.5% (in 10 of 16 patients). To differentially diagnose between synchronous and metachronous primary cancers and secondary ones (metastatic) the clinical data may be value, first of all, the degree of spread of the tumor process and its localization. Therapeutic policy obligatory takes account of the primary or metastatic origin of a tumor in the opposite mammary gland. Sectorial resection of a symmetric portion of the second mammary gland simultaneously with mastectomy is indicated in case of clinical, roentgenological or cytologic suspicions of a neoplasm in it.